Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 9/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1179225 | 0.84 | ADRB2 (0.53) | ADRB2 | |
| SCHEMBL3580545 | 0.84 | ADRB2 (0.58) | ADRB2CYP1A2SIGMAR1MC4RHDAC1 | |
| SCHEMBL1179648 | 0.82 | ADRB2 (0.53) | ADRB2CYP1A2KDM4E | |
| SCHEMBL3592477 | 0.80 | ADRB2 (0.40) | ADRB2CYP1A2MC4RBCHEKDM4E | |
| Oxalic Acid SCHEMBL3807723 | 0.76 | KDM4E (0.49) | ADRB2CYP1A2SIGMAR1KDM4E | |
| SCHEMBL12193249 | 0.76 | ADRB2 (0.54) | ADRB2 | |
| SCHEMBL3817577 | 0.76 | SIGMAR1 (0.50) | ADRB2CYP1A2SIGMAR1BCHEKDM4E | |
| SCHEMBL12193241 | 0.74 | ADRB2 (0.54) | ADRB2CYP1A2MC4RKDM4E | |
| SCHEMBL3577973 | 0.72 | ADRB2 (0.54) | ADRB2KDM4E | |
| SCHEMBL14139271 | 0.71 | ADRB2 (0.49) | ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210688-A1 | Novel Benzothiazolone Derivatives | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-7709511-B2 | Benzothiazolone derivatives | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20080300275-A1 | Novel Benzothiazolone Derivatives | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300275-A1 | Novel Benzothiazolone Derivatives | NR0B1, RB1, CCND1 | ADRB2 156/4885CYP1A2 481/4885MME 3467/4885 |
| US-20100210688-A1 | Novel Benzothiazolone Derivatives | NR0B1, RB1, CCND1 | ADRB2 156/4885CYP1A2 481/4885MME 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.